Highlighting key issues and differences among GMPs of Europe,
Canada, and the WHO, this reference examines US law and
governmental policy affecting domestic and multinational
pharmaceutical manufacturing. The book recommend pragmatic ways to
interpret and comply with FDA CGMP regulation and related criteria.
They focus on geographical redistribution of manufacturing
facilities, accommodation of a diversity of regulatory and
statutory governance,... more...